Literature DB >> 11757866

Dedifferentiated liposarcoma.

A G Nascimento1.   

Abstract

Dedifferentiated liposarcoma is a high-grade nonlipogenic sarcoma that arises in a background of a preexisting well-differentiated liposarcoma. The phenomenon of dedifferentiation is time dependent, and primary or de novo tumors exceed secondary neoplasms in a ratio of 9:1. The tumor occurs most frequently in adults beyond the 6th decade of life, slightly predominates in men, and involves the abdominal cavity most often. Pleomorphic malignant fibrous histiocytoma-like histologic features are the most commonly observed phenotype, although other sarcomatous phenotypes have been described less frequently. Surgical treatment is the main form of therapy for dedifferentiated liposarcoma, which is associated with a reported local recurrence rate of 41% to 52%, 15% distant metastatic rate, and 30% disease-related mortality rate. On a chromosomal level, dedifferentiated liposarcoma frequently displays the same chromosomal abnormality associated with well-differentiated liposarcomas--ie, the presence of a supernumerary ring or giant chromosome derived from the 12q(13-15) region.

Entities:  

Mesh:

Year:  2001        PMID: 11757866

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  15 in total

1.  A case of eccrine porocarcinoma: usefulness of immunostain for s-100 protein in the diagnoses of recurrent and metastatic dedifferentiated lesions.

Authors:  Yoshitaka Kurisu; Motomu Tsuji; Emi Yasuda; Yuro Shibayama
Journal:  Ann Dermatol       Date:  2013-08-13       Impact factor: 1.444

Review 2.  Dedifferentiated liposarcoma of the oral cavity with angiosarcomatous dedifferentiation.

Authors:  Isabela Werneck da Cunha; Luiz Paulo Kowalski; Fernando Augusto Soares
Journal:  Virchows Arch       Date:  2005-04-02       Impact factor: 4.064

Review 3.  Liposarcoma: a soft tissue tumor with many presentations.

Authors:  H J Mankin; K P Mankin; D C Harmon
Journal:  Musculoskelet Surg       Date:  2014-07-22

4.  Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.

Authors:  Hiroaki Kimura; Yoh Dobashi; Takayuki Nojima; Hiroyuki Nakamura; Norio Yamamoto; Hiroyuki Tsuchiya; Hiroko Ikeda; Seiko Sawada-Kitamura; Takeru Oyama; Akishi Ooi
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

Review 5.  The histological variants of liposarcoma: predictive MRI findings with prognostic implications, management, follow-up, and differential diagnosis.

Authors:  Magda Rizer; Adam D Singer; Mark Edgar; Jean Jose; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2016-05-21       Impact factor: 2.199

6.  Giant Retroperitoneal Mucinous Tumor Supportively Diagnosed as a Dedifferentiated Liposarcoma by Fluorescence In Situ Hybridization of MDM2 Gene.

Authors:  Taku Naiki; Shuzo Hamamoto; Noriyasu Kawai; Aya Naiki-Ito; Yoshiyuki Kojima; Takahiro Yasui; Keiichi Tozawa; Kenjiro Kohri
Journal:  ISRN Urol       Date:  2011-06-16

7.  The incidence and relevance of non-fatty components in trunk and extremity lipomatous soft tissue masses.

Authors:  Rupert Berkeley; Odinakachukwu Okereke; Karan Malhotra; Asif Saifuddin
Journal:  Br J Radiol       Date:  2021-05-20       Impact factor: 3.629

8.  Fluorescence In Situ Hybridization for MDM2 Amplification as a Routine Ancillary Diagnostic Tool for Suspected Well-Differentiated and Dedifferentiated Liposarcomas: Experience at a Tertiary Center.

Authors:  Khin Thway; Jayson Wang; John Swansbury; Toon Min; Cyril Fisher
Journal:  Sarcoma       Date:  2015-02-25

9.  An unusual case of primary colonic dedifferentiated liposarcoma.

Authors:  Mehmet Akif Türkoğlu; Gülsüm Özlem Elpek; Volkan Doğru; Hasan Calış; Aslı Uçar; Cumhur Arıcı
Journal:  Int J Surg Case Rep       Date:  2013-11-14

10.  A unique dedifferentiated tumor of the retroperitoneum.

Authors:  Shahzeer Karmali; Halligrimur Benediktson; Walley Temple; Oliver F Bathe
Journal:  World J Surg Oncol       Date:  2004-07-23       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.